m6A RNA甲基化与皮肤黑素瘤相关性的研究进展

doi:10.35541/cjd.20210064

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (9): 889-892.doi: 10.35541/cjd.20210064

m6A RNA甲基化与皮肤黑素瘤相关性的研究进展

谌芳琪梁闫吴婷黄长征

华中科技大学同济医学院附属协和医院皮肤科，武汉 430022

收稿日期:2021-01-21 修回日期:2021-09-25 发布日期:2023-09-07
通讯作者: 黄长征 E-mail:hcz0501@126.com
基金资助:
国家自然科学基金（81972565）

Associations between m6A RNA methylation and cutaneous melanoma

Chen Fangqi, Liang Yan, Wu Ting, Huang Changzheng

Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Received:2021-01-21 Revised:2021-09-25 Published:2023-09-07
Contact: Huang Changzheng E-mail:hcz0501@126.com
Supported by:
National Natural Science Foundation of China（81972565）

摘要/Abstract

摘要： 【摘要】 N6-甲基腺苷（m6A）修饰可通过影响RNA的稳定性、核运输、翻译效率、剪接及降解影响基因表达。目前研究表明，m6A修饰与黑素瘤的增殖、转移及免疫治疗抵抗等生物学行为相关，具体机制仍待研究。该文综述了m6A RNA甲基化修饰的调控及其在黑素瘤中的生物学行为及机制。

关键词: 黑色素瘤, RNA甲基化, N6-甲基腺苷

Abstract: 【Abstract】 N6-methyladenosine （m6A） modification can regulate gene expression by influencing RNA stability, nuclear transport, translation efficiency, alternative splicing and degradation. Current studies have shown that m6A modification is associated with multiple biological behaviors of melanoma, such as proliferation, metastasis and resistance to immunotherapy, but specific mechanisms still need further study. This review summarizes the regulation of m6A RNA methylation, and its related biological behaviors and mechanisms of action in melanoma.

Key words: Melanoma, RNA methylation, m6A

谌芳琪梁闫吴婷黄长征. m6A RNA甲基化与皮肤黑素瘤相关性的研究进展[J]. 中华皮肤科杂志, 2023,56(9):889-892. doi:10.35541/cjd.20210064

Chen Fangqi, Liang Yan, Wu Ting, Huang Changzheng. Associations between m6A RNA methylation and cutaneous melanoma[J]. Chinese Journal of Dermatology, 2023, 56(9): 889-892.doi:10.35541/cjd.20210064

参考文献 33

［1］	Garcias Morales D, Reyes JL. A birds′⁃eye view of the activity and specificity of the mRNA m6A methyltransferase complex［J/OL］. Wiley Interdiscip Rev RNA, 2021,12（1）:e1618. doi: 10. 1002/wrna.1618.
［2］	Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation［J］. Nat Rev Mol Cell Biol, 2019,20（10）:608⁃624. doi: 10.1038/s41580⁃019⁃0168⁃5.
［3］	Huang W, Chen TQ, Fang K, et al. N6⁃methyladenosine methyltransferases: functions, regulation, and clinical potential［J］. J Hematol Oncol, 2021,14（1）:117. doi: 10.1186/s13045⁃021⁃01129⁃8.
［4］	Ping XL, Sun BF, Wang L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6⁃methyladenosine methyltransferase［J］. Cell Res, 2014,24（2）:177⁃189. doi: 10.1038/cr.2014.3.
［5］	Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation［J］. Cell Discov, 2018,4:10. doi: 10.1038/s41421⁃018⁃0019⁃0.
［6］	Patil DP, Chen CK, Pickering BF, et al. m6A RNA methylation promotes XIST⁃mediated transcriptional repression［J］. Nature, 2016,537（7620）:369⁃373. doi: 10.1038/nature19342.
［7］	Knuckles P, Lence T, Haussmann IU, et al. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA⁃binding factor Rbm15/Spenito to the m6A machinery component Wtap/Fl（2）d［J］. Genes Dev, 2018,32（5⁃6）:415⁃429. doi: 10. 1101/gad.309146.117.
［8］	Bawankar P, Lence T, Paolantoni C, et al. Hakai is required for stabilization of core components of the m6A mRNA methylation machinery［J］. Nat Commun, 2021,12（1）:3778. doi: 10.1038/s41467⁃021⁃23892⁃5.
［9］	Zhao X, Yang Y, Sun BF, et al. FTO⁃dependent demethylation of N6⁃methyladenosine regulates mRNA splicing and is required for adipogenesis［J］. Cell Res, 2014,24（12）:1403⁃1419. doi: 10. 1038/cr.2014.151.
［10］	Tang C, Klukovich R, Peng H, et al. ALKBH5⁃dependent m6A demethylation controls splicing and stability of long 3′⁃UTR mRNAs in male germ cells［J/OL］. Proc Natl Acad Sci U S A, 2018,115（2）:E325⁃E333. doi: 10.1073/pnas.1717794115.
［11］	Roundtree IA, He C. Nuclear m6A reader YTHDC1 regulates mRNA splicing［J］. Trends Genet, 2016,32（6）:320⁃321. doi: 10. 1016/j.tig.2016.03.006.
［12］	Roundtree IA, Luo GZ, Zhang Z, et al. YTHDC1 mediates nuclear export of N6⁃methyladenosine methylated mRNAs［J/OL］. Elife, 2017,6:e31311. doi: 10.7554/eLife.31311.
［13］	Hsu PJ, Zhu Y, Ma H, et al. Ythdc2 is an N6⁃methyladenosine binding protein that regulates mammalian spermatogenesis［J］. Cell Res, 2017,27（9）:1115⁃1127. doi: 10.1038/cr.2017.99.
［14］	Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N6⁃methyladenosine⁃modified RNA［J］. Cell Res, 2017,27（3）:315⁃328. doi: 10.1038/cr.2017.15.
［15］	Dai XY, Shi L, Li Z, et al. Main N6⁃methyladenosine readers: YTH family proteins in cancers［J］. Front Oncol, 2021,11:635329. doi: 10.3389/fonc.2021.635329.
［16］	Huang H, Weng H, Sun W, et al. Recognition of RNA N6⁃methyladenosine by IGF2BP proteins enhances mRNA stability and translation［J］. Nat Cell Biol, 2018,20（3）:285⁃295. doi: 10.1038/s41556⁃018⁃0045⁃z.
［17］	Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease［J］. Hum Genet, 2016,135（8）:851⁃867. doi: 10.1007/s00439⁃016⁃1683⁃5.
［18］	Valášek LS, Zeman J, Wagner S, et al. Embraced by eIF3: structural and functional insights into the roles of eIF3 across the translation cycle［J］. Nucleic Acids Res, 2017,45（19）:10948⁃10968. doi: 10.1093/nar/gkx805.
［19］	Gao R, Ye M, Liu B, et al. m6A modification: a double⁃edged sword in tumor development［J］. Front Oncol, 2021,11:679367. doi: 10.3389/fonc.2021.679367.
［20］	Gide TN, Wilmott JS, Scolyer RA, et al. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma［J］. Clin Cancer Res, 2018,24（6）:1260⁃1270. doi: 10. 1158/1078⁃0432.CCR⁃17⁃2267.
［21］	Lin Y, Wang S, Liu S, et al. Identification and verification of molecular subtypes with enhanced immune infiltration based on m6A regulators in cutaneous melanoma［J］. Biomed Res Int, 2021,2021:2769689. doi: 10.1155/2021/2769689.
［22］	Iles MM, Law MH, Stacey SN, et al. A variant in FTO shows association with melanoma risk not due to BMI［J］. Nat Genet, 2013,45（4）:428⁃432. doi: 10.1038/ng.2571.
［23］	Yang S, Wei J, Cui YH, et al. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti⁃PD⁃1 blockade［J］. Nat Commun, 2019,10（1）:2782. doi: 10.1038/s41467⁃019⁃10669⁃0.
［24］	Dahal U, Le K, Gupta M. RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2［J］. Melanoma Res, 2019,29（4）:382⁃389. doi: 10.1097/CMR.0000000000000580.
［25］	Luo G, Xu W, Zhao Y, et al. RNA m6A methylation regulates uveal melanoma cell proliferation, migration, and invasion by targeting c⁃Met［J］. J Cell Physiol, 2020,235（10）:7107⁃7119. doi: 10.1002/jcp.29608.
［26］	Kim T, Havighurst T, Kim K, et al. Targeting insulin⁃like growth factor 2 mRNA⁃binding protein 1 （IGF2BP1） in metastatic melanoma to increase efficacy of BRAFV600E inhibitors［J］. Mol Carcinog, 2018,57（5）:678⁃683. doi: 10.1002/mc.22786.
［27］	Karras P, Riveiro⁃Falkenbach E, Cañón E, et al. p62/SQSTM1 fuels melanoma progression by opposing mRNA decay of a selective set of pro⁃metastatic factors［J］. Cancer Cell, 2019,35（1）:46⁃63.e10. doi: 10.1016/j.ccell.2018.11.008.
［28］	Ghoshal A, Rodrigues LC, Gowda CP, et al. Extracellular vesicle⁃dependent effect of RNA⁃binding protein IGF2BP1 on melanoma metastasis［J］. Oncogene, 2019,38（21）:4182⁃4196. doi: 10.1038/s41388⁃019⁃0797⁃3.
［29］	Hanniford D, Ulloa⁃Morales A, Karz A, et al. Epigenetic silencing of CDR1as drives IGF2BP3⁃mediated melanoma invasion and metastasis［J］. Cancer Cell, 2020,37（1）:55⁃70.e15. doi: 10.1016/j.ccell.2019.12.007.
［30］	Chu M, Wan H, Zhang X. Requirement of splicing factor hnRNP A2B1 for tumorigenesis of melanoma stem cells［J］. Stem Cell Res Ther, 2021,12（1）:90. doi: 10.1186/s13287⁃020⁃02124⁃5.
［31］	Li T, Gu M, Deng A, et al. Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis［J］. Cancer Cell Int, 2020,20:239. doi: 10.1186/s12935⁃020⁃01309⁃5.
［32］	Li N, Kang Y, Wang L, et al. ALKBH5 regulates anti⁃PD⁃1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment［J］. Proc Natl Acad Sci U S A, 2020,117（33）:20159⁃20170. doi: 10.1073/pnas.1918 986117.
［33］	Jia R, Chai P, Wang S, et al. m6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation［J］. Mol Cancer, 2019,18（1）:161. doi: 10.1186/s12943⁃019⁃1088⁃x.

[1]	袁心刚倪思利张建罗晓燕王华. 儿童黑素细胞痣的诊疗水平亟待提高[J]. 中华皮肤科杂志, 2023, 56(8): 782-786.
[2]	陈怡宋秀祖. 瞬时受体电位通道在黑素细胞中的作用及相关疾病研究[J]. 中华皮肤科杂志, 2023, 56(4): 376-379.
[3]	张付贺石磊罗敏刘沛范晴王秀丽. SKH-1小鼠黑素瘤B16F10细胞种植瘤模型的建立[J]. 中华皮肤科杂志, 2023, 0(3): 20210689-e20210689.
[4]	湛锦杉玄秀云曹娟梅谌芳琪黄长征. 抗黑素瘤分化相关基因5抗体阳性皮肌炎治疗进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220368-e20220368.
[5]	张宁李舒李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609.
[6]	夏利杨林洪许丽孙文国于亮翟婉芳王东霞邝小湾. 微小RNA-181b-5p对皮肤黑素瘤细胞株增殖和侵袭的作用及机制研究[J]. 中华皮肤科杂志, 2022, 55(7): 588-595.
[7]	刘影易秀莉叶竹标高天文朱冠男. 源于中国人转移性黑素瘤细胞株的建立及其生物学特性研究[J]. 中华皮肤科杂志, 2022, 55(5): 375-381.
[8]	陈欣琪赵娟王朋李婷婷于世荣康晓静. 皮肤黑素瘤94例临床病理特点与基因突变的关系[J]. 中华皮肤科杂志, 2022, 55(5): 395-400.
[9]	张晓陈凤鸣柳琳罗莉郭金高天文石琼. Ⅰ期皮肤黑素瘤163例临床病理特征及预后分析[J]. 中华皮肤科杂志, 2022, 55(5): 389-394.
[10]	王海彦鄢洁曹馨元石长青刘菁陆晓鸥张嘉莉陈宏泉. 基于SEER数据库的肢端雀斑样痣黑素瘤预后分析[J]. 中华皮肤科杂志, 2022, 55(5): 411-416.
[11]	李婷婷赵娟王鹏刘冬梅康晓静. 阿扎胞苷对黑素瘤A375细胞HOXA9基因表达及生物学行为的影响[J]. 中华皮肤科杂志, 2022, 55(10): 858-863.
[12]	吴清容高鑫鲁丽霞李芳芳陈明亮赵爽陈翔粟娟. 机械应力与黑素瘤：129例足底黑素瘤的回顾性分析[J]. 中华皮肤科杂志, 2022, 55(10): 850-853.
[13]	李婷婷关猛猛赵娟康晓静. 单细胞转录组测序在黑素瘤研究中的应用[J]. 中华皮肤科杂志, 2022, 0(1): 20210191-e20210191.
[14]	陈雁雁张翰林刘莉萍李遇梅. 昼夜节律与黑素瘤相关性的研究进展[J]. 中华皮肤科杂志, 2022, 0(1): 20220173-e20220173.
[15]	姚晓东崔晓美刘晓宇吴晓琰沈聪聪陈晓栋. 长链非编码RNA 068在黑素瘤细胞迁移中的功能研究[J]. 中华皮肤科杂志, 2022, 55(1): 31-39.

m6A RNA甲基化与皮肤黑素瘤相关性的研究进展

Associations between m6A RNA methylation and cutaneous melanoma

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

Metrics

本文评价

推荐阅读 10